It's Not Pretty as Avon Leads 10 Stocks To the Woodshed

NEW YORK ( TheStreet) -- The earnings woodshed is getting crowded as Avon Products ( AVP) led 10 companies to the woodshed last week. Among these stocks Avon was the only one of the 10 that was upgraded to buy on its share price weakness.

Buy-And-Trade Parameters from the Woodshed

Avon Products ($17.74) missed EPS estimates by 5 cents earning 14 cents a share premarket on Thursday. The stock closed at $22.40 on Wednesday and crashed below its 50-day and 200-day simple moving averages at $20.64 and $21.12 to a low of $17.02 on Thursday. Share price weakness resulted in an upgrade to buy from hold according to www.ValuEngine.com. The maker of beauty products has an annual value level at $12.83 with a quarterly pivot at $17.36, a semiannual pivot at $19.81 and weekly risky level at $21.05.

Boyd Gaming ( BYD) ($10.21) missed EPS estimates by 9 cents reporting a loss of 8 cents a share in premarket trading on Thursday. The stock plunged from $12.98 at the close on Wednesday to a low of $10.11 on Monday well below its 200-day SMA at $10.88. The hold rated gaming company has a semiannual value level at $9.29 with a quarterly risky level at $13.78.

Con-way ( CNW) ($41.73) missed EPS estimates by 4 cents earning 58 cents a share in afterhours trading on Wednesday. The sell rated trucker detoured to the woodshed as the stock plunged below its 50-day SMA at $43.42 to a low of $40.15 on Thursday. The 200-day SMA is $38.74 with a semiannual pivot at $41.77 and monthly risky level at $43.63.

Crocs ( CROX) ($12.45) missed EPS estimates by a penny earning 17 cents a share in afterhours trading on Wednesday. By the end of last week the hold rated maker of colorful footwear set a new 52-week low at $11.96. My quarterly value level is $7.64 with a weekly pivot at $13.04 and a monthly risky level at $13.75.

Novo Nordisk ( NVO) ($168.42) reported quarterly results on Thursday earning $2.20 per share. The buy rated pharmaceutical company that concentrates on products for the treatment of diabetes fell below its 50-day and 200-day SMAs at $170.09 and $169.88 with a monthly value level at $156.69 and a semiannual risky level at $174.38.

If you liked this article you might like

Is an Avon Bottom Calling?

Avon Still Has Value But Isn't Investable, Barclays Says

Closing Bell: Another Record for Dow Stretches Streak Into Day Seven; Avon Tumbles